Literature DB >> 32286710

FAK Promotes Early Osteoprogenitor Cell Proliferation by Enhancing mTORC1 Signaling.

Shuqun Qi1,2,3,4, Xiumei Sun4,5, Han Kyoung Choi4, Jinfeng Yao4,6, Li Wang4, Guomin Wu4,5, Yun He4,7, Jian Pan1,2,3, Jun-Lin Guan8, Fei Liu4.   

Abstract

<span class="Gene">Focal adhesion kinase (<span class="Gene">FAK) has important functions in bone homeostasis but its role in early osteoprogenitor cells is unknown. We show herein that mice lacking FAK in Dermo1-expressing cells exhibited low bone mass and decreased osteoblast number. Mechanistically, FAK-deficient early osteoprogenitor cells had decreased proliferation and significantly reduced mammalian/mechanistic target of rapamycin complex 1 (mTORC1) signaling, a central regulator of cell growth and proliferation. Furthermore, our data showed that the pharmacological inhibition of FAK kinase-dependent function alone was sufficient to decrease the proliferation and compromise the mineralization of early osteoprogenitor cells. In contrast to the Fak deletion in early osteoprogenitor cells, FAK loss in Col3.6 Cre-targeted osteoblasts did not cause bone loss, and Fak deletion in osteoblasts did not affect proliferation, differentiation, and mTORC1 signaling but increased the level of active proline-rich tyrosine kinase 2 (PYK2), which belongs to the same non-receptor tyrosine kinase family as FAK. Importantly, mTORC1 signaling in bone marrow stromal cells (BMSCs) was reduced if FAK kinase was inhibited at the early osteogenic differentiation stage. In contrast, mTORC1 signaling in BMSCs was not affected if FAK kinase was inhibited at a later osteogenic differentiation stage, in which, however, the concomitant inhibition of both FAK kinase and PYK2 kinase reduced mTORC1 signaling. In summary, our data suggest that FAK promotes early osteoprogenitor cell proliferation by enhancing mTORC1 signaling via its kinase-dependent function and the loss of FAK in osteoblasts can be compensated by the upregulated active PYK2.
© 2020 American Society for Bone and Mineral Research. © 2020 American Society for Bone and Mineral Research.

Entities:  

Keywords:  FAK; OSTEOBLAST; OSTEOPROGENITOR; PYK2; mTORC1

Mesh:

Substances:

Year:  2020        PMID: 32286710      PMCID: PMC7486225          DOI: 10.1002/jbmr.4029

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  41 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

Review 2.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 3.  Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions.

Authors:  Michael D Schaller
Journal:  J Cell Sci       Date:  2010-04-01       Impact factor: 5.285

4.  FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3-kinase-Akt pathways.

Authors:  Daisuke Yamamoto; Yoshiko Sonoda; Maki Hasegawa; Megumi Funakoshi-Tago; Eriko Aizu-Yokota; Tadashi Kasahara
Journal:  Cell Signal       Date:  2003-06       Impact factor: 4.315

5.  The effect of conditional inactivation of beta 1 integrins using twist 2 Cre, Osterix Cre and osteocalcin Cre lines on skeletal phenotype.

Authors:  Asha Shekaran; James T Shoemaker; Taylor E Kavanaugh; Angela S Lin; Michelle C LaPlaca; Yuhong Fan; Robert E Guldberg; Andrés J García
Journal:  Bone       Date:  2014-08-27       Impact factor: 4.398

Review 6.  Focal adhesion kinase in integrin signaling.

Authors:  J L Guan
Journal:  Matrix Biol       Date:  1997-10       Impact factor: 11.583

Review 7.  Genetic mouse models for bone studies--strengths and limitations.

Authors:  Florent Elefteriou; Xiangli Yang
Journal:  Bone       Date:  2011-08-31       Impact factor: 4.398

8.  Osteopenia in transgenic mice with osteoblast-targeted expression of the inducible cAMP early repressor.

Authors:  Taranpreet K Chandhoke; Yu-Feng Huang; Fei Liu; Gloria A Gronowicz; Douglas J Adams; John R Harrison; Barbara E Kream
Journal:  Bone       Date:  2008-03-29       Impact factor: 4.398

Review 9.  Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  David W Dempster; Juliet E Compston; Marc K Drezner; Francis H Glorieux; John A Kanis; Hartmut Malluche; Pierre J Meunier; Susan M Ott; Robert R Recker; A Michael Parfitt
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

Review 10.  Targeting FAK in human cancer: from finding to first clinical trials.

Authors:  Vita M Golubovskaya
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01
View more
  1 in total

1.  Chondrocyte Tsc1 controls cranial base bone development by restraining the premature differentiation of synchondroses.

Authors:  Yuan-Lynn Hsieh; Xiaoxi Wei; Yating Wang; Honghao Zhang; Shuqun Qi; Di Xie; Yuji Mishina; Daniela Mendonça; Nan Hatch; Fei Liu
Journal:  Bone       Date:  2021-08-05       Impact factor: 4.398

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.